Serum Institute of India

Mosquito against yellow background
#Immunology / Virology & Vaccines #Malaria #Novavax #Serum Institute of India #University of Oxford #WHO

WHO recommends new cost-effective malaria vaccine

The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). Developed by The University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant technology, R21/Matrix-M malaria vaccine demonstrates high efficacy with… Read More

#News #Regulatory #Trending News

Malaria vaccine
#Africa #Immunology / Virology & Vaccines #Malaria #Regulatory #Serum Institute of India #University of Oxford #Vaccines

Ghana vaccine approval a ‘critical step’ in combatting malaria

The R21/Matrix-M malaria vaccine has received regulatory clearance for use in Ghana by the country’s Food and Drugs Authority, making it the first country to approve the vaccine. R21/Matrix-M was developed by the University of Oxford and manufactured and scaled up by the Serum Institute of India (SIIPL), leveraging Novavax’s… Read More

#News #Regulatory #Trending News